Eisai dials back forecasts for Alzheimer's drug Leqembi | pharmaphorum
https://pharmaphorum.com/news/eisai-dials-back-forecasts-alzheimers-drug-leqembi
Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish.
In its six-month financial report for the current fiscal year published this morning, the Japanese drugmaker revealed Leqembi (lecanemab) sales came in at JPY 16.3 billion (around $107 million), of which around JPY 10.5 billion came from the US.
https://pharmaphorum.com/news/eisai-dials-back-forecasts-alzheimers-drug-leqembi
Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish.
In its six-month financial report for the current fiscal year published this morning, the Japanese drugmaker revealed Leqembi (lecanemab) sales came in at JPY 16.3 billion (around $107 million), of which around JPY 10.5 billion came from the US.